The OncoAlert Network 🚨

oncoalert.bsky.social

30 January 2026 11:24

NEXT FRIDAY February 6 2026: 6th Annual OncoAlert Colloquium🚨 REGISTER👉https://t.co/6xGZCRtrTK Day 5 February 6, 2026 #LungCancer 🫁& @CancerCareMASCC Sessions As ALWAYS ✅PATIENTS INCLUDED

Mirrors of Medicine

mirrorsofmedicine.bsky.social

30 January 2026 10:15

Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: www.clinical-genitourinary-cancer.com/article/S155... @drkarinetawagi.bsky.social @vadimkoshkin.bsky.social @erplimackmd.bsky.social Peter H. O’Donnel

The OncoAlert Network 🚨

oncoalert.bsky.social

22 May 2025 10:04

The OncoAlert🚨ROUND UP Now Out‼️ Covering May 15-22, 2025 REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... youtu.be/xgIw0BISCpo @elisaagostinetto.bsky.social @barbaramelao.bsky.social @elisaagostinetto.bsky.social @icromeattini.bsky.social @realbowtiedoc.bsky.social

The OncoAlert Network 🚨

oncoalert.bsky.social

20 May 2025 16:19

Oncology Here & Now Pod/Web Cast🚨 Join Urology colleagues, Dr. @barbaramelao.bsky.social 🇧🇷and Dr. Philippe Spiess🇺🇸, as they discuss upper tract urothelial carcinoma—from risk stratification to management strategies in both low-risk and high-risk, high-grade settings. youtu.be/pfkLTzWX4AU

The OncoAlert Network 🚨

oncoalert.bsky.social

09 May 2025 11:32

NEWS FROM INDUSTRY Astra Zeneca reports that the POTOMAC Phase III trial demonstrated that adding 1yr durvalumab to standard Bacillus Calmette-Guérin induction and maintenance therapy significantly improved DGS in high-risk non-muscle-invasive #BladderCancer www.astrazeneca.com/media-centre...